Biogen (BSP:BIIB34) Pre-Tax Income

: R$19,048 Mil (TTM As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Biogen's pretax income for the three months ended in Mar. 2023 was R$2,283 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2023 was R$19,048 Mil. Biogen's pretax margin was 17.80%.

During the past 13 years, Biogen's highest Pretax Margin was 49.56%. The lowest was 15.89%. And the median was 41.23%.

Biogen Pre-Tax Income Historical Data

The historical data trend for Biogen's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

22,910.51

29,248.26

25,967.87

9,868.93

18,840.43

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Pre-Tax Income																1,728.80	6,408.06	7,189.50	3,167.17	2,282.93

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Pre-Tax Income Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Biogen's Pre-Tax Income falls in comparison to its industry or sector. The grey bar indicates the Pre-Tax Income's extreme value range as defined by GuruFocus.

Biogen Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Biogen's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	15221.626	+	4443.903	+	-1293.516	+	468.414	+	0.0010000000002037
	=	18,840

Biogen's Pretax Income for the quarter that ended in Mar. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	2694.409	+	-507.318	+	-325.538	+	421.376	+	0
	=	2,283

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$19,048 Mil.

Biogen (BSP:BIIB34) Pre-Tax Income Explanation

Biogen's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	2282.929	/	12828.782
	=	17.80%

During the past 13 years, Biogen's highest Pretax Margin was 49.56%. The lowest was 15.89%. And the median was 41.23%.

Biogen Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Biogen's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines